ArticleJournal of surgical oncology2019
Lymphadenectomy during pulmonary metastasectomy: Impact on survival and recurrence.
Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- Prognostic significance of lymph nodes assessment during pulmonary metastasectomy: a systematic review and meta-analysis.Journal of thoracic disease · 2023Article
- The prognostic effect of lymph node dissection in secondary lung tumor metastasectomies.Turk gogus kalp damar cerrahisi dergisi · 2022Article
- Effects of mediastinal lymph node dissection in colorectal cancer-related pulmonary metastasectomy.Thoracic cancer · 2021Article
- Factors influencing the effect of surgical treatment in secondary proliferative disease with lung involvement.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2021Article
- Results of redo pulmonary metastasectomy.Journal of thoracic disease · 2021Review
- Lymphadenectomy in pulmonary metastasectomy.Journal of thoracic disease · 2021Review
- Lymphadenectomy during pulmonary metastasectomy: Impact on survival and recurrence.Journal of surgical oncology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesLymphadenectomy during pulmonary metastasectomy (PM) is widely carried out. We assessed the potential benefit on patient survival and tumor recurrence of this practice.
methodsOne hundred eighty-one patients undergoing a first PM were studied. Eighty-six patients (47.5%) underwent lymphadenectomy (L+ group) whereas 95 (52.5%) did not undergo nodal harvesting (L-group). Main outcomes were overall survival (OS) and disease-free survival (DFS). Median follow-up was 25 months (interquartile range [IQR], 13-49).
resultsAt follow-up 84 patients (46.4%) died, whereas 97 (53.6%) were still alive with recurrence in 78 patients (43%). There was no difference in 5-year survival (L+ 30.0% vs L- 43.2%; P = .87) or in the 5-year cumulative incidence of recurrence (L + 63.2% vs L-80%; P = .07) between the two groups. Multivariable analysis indicated that disease-free interval (DFI) less than 29 months (P < .001) and lung comorbidities (P = .003) were significant predictors of death. Metastases from non-small-cell lung cancer increased the risk of lung comorbidities by a factor of 19.8, whereas the risk of DFI less than 29 months was increased nearly 11-fold. Competing risk regression identified multiple metastases (P = .004), head/neck primary tumor (P = .009), and age less than 67 years (P = .024) as independent risk factors for recurrence.
conclusionAssociated lymphadenectomy showed not to give any additional advantage in terms of survival and recurrence after PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.